Top

BMC Nephrology

Published in:

Open Access 01-12-2021 | Interstitial Nephritis | Study protocol

Prednisolone treatment in acute interstitial nephritis (PRAISE) – protocol for the randomized controlled trial

Authors: Frank H. Mose, Henrik Birn, Nikolai Hoffmann-Petersen, Jesper N. Bech

Published in: BMC Nephrology | Issue 1/2021

Abstract

Background

Acute interstitial nephritis (AIN) is an important and common cause of acute renal failure. There are no generally accepted guidelines for the treatment of AIN, due to the lack of prospective randomized trials. Since AIN is characterized by an enhanced immune response, immunosuppressive treatment could potentially improve prognosis by attenuating inflammation and subsequent fibrosis. Despite the limited evidence of effects of steroids and potential adverse effects, prednisolone is frequently used in the treatment of AIN and there is a strong need for clinical trials on the effects of immunosuppression, including steroids, in the treatment of AIN. We aimed to evaluate the effectiveness of prednisolone treatment in AIN, and hypothesized a positive effect of prednisolone treatment on renal function in AIN.

Methods

The study is a randomized, controlled, prospective, open label multicenter study, including incident adult patients with biopsy proven AIN. Patients will be randomized 1:1 to one of 2 treatment regimens:

No prednisolone treatment (control group) and

B) Oral prednisolone treatment staring with 60 mg daily tapered over 8 weeks.

One hundred ten patients (55 in each group) are planned to be included and followed for 1 year. Primary outcome is renal function estimated by eGFR 3 months after inclusion. Secondary outcomes are renal function after 12 months and need for renal replacement therapy and quality of life after 3 and 12 months. In addition, with-in prednisolone group analysis are performed to estimate the importance of treatment delay. Exploratory analyses include analysis of biomarkers in urine and plasma and the evaluation of these biomarkers in relation to renal prognosis and re-evaluation of renal biopsies to identify possible renal prognostic factors.

Discussion

Strengths and possible limitations in the design are evaluated. The study will provide important information on the effects of prednisolone treatment in AIN and as well as prognostic information relevant for future use of biomarkers and histology. Ultimately, this would lead to improved and evidence based clinical guidelines for the treatment of AIN.

Trial registration

ClinicalTrials.gov identifier NCT04376216 (Retrospectively registered on May 6, 2020).

Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913–7. https://doi.org/10.1097/01.CCM.0000224227.70642.4F.CrossRefPubMed

Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18:1292–8. https://doi.org/10.1681/ASN.2006070756.CrossRefPubMed

Farrington K, Levison DA, Greenwood RN, Cattell WR, Baker LR. Renal biopsy in patients with unexplained renal impairment and normal kidney size. Q J Med. 1989;70:221–33 http://www.ncbi.nlm.nih.gov/pubmed/2602535. Accessed 30 Nov 2016.PubMed

Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis. 2000;35:433–47 http://www.ncbi.nlm.nih.gov/pubmed/10692269. Accessed 1 Dec 2016.CrossRef

Raghavan R, Eknoyan G. Acute interstitial nephritis - a reappraisal and update. Clin Nephrol. 2014;82:149–62 http://www.ncbi.nlm.nih.gov/pubmed/25079860. Accessed 1 Dec 2016.CrossRef

Clarkson MR, Giblin L, O’Connell FP, O’Kelly P, Walshe JJ, Conlon P, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19:2778–83. https://doi.org/10.1093/ndt/gfh485.CrossRefPubMed

Yeun JY, Ornt DB, Depner TA. Brenner and Rector’s The Kidney; 2012. https://doi.org/10.1016/B978-1-4160-6193-9.10064-8.CrossRef

Buysen JG, Houthoff HJ, Krediet RT, Arisz L. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant. 1990;5:94–9 http://www.ncbi.nlm.nih.gov/pubmed/2113219. Accessed 1 Dec 2016.CrossRef

Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804–17. https://doi.org/10.1046/j.1523-1755.2001.060002804.x.CrossRefPubMed

10.

Kida H, Abe T, Tomosugi N, Koshino Y, Yokoyama H, Hattori N. Prediction of the long-term outcome in acute interstitial nephritis. Clin Nephrol. 1984;22:55–60 http://www.ncbi.nlm.nih.gov/pubmed/6478672. Accessed 1 Dec 2016.PubMed

11.

Bhaumik SK, Kher V, Arora P, Rai PK, Singhal M, Gupta A, et al. Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail. 1996;18:97–104 http://www.ncbi.nlm.nih.gov/pubmed/8820506. Accessed 1 Dec 2016.CrossRef

12.

Pusey CD, Saltissi D, Bloodworth L, Rainford DJ, Christie JL. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med. 1983;52:194–211 http://www.ncbi.nlm.nih.gov/pubmed/6604293. Accessed 1 Dec 2016.PubMed

13.

Koselj M, Kveder R, Bren AF, Rott T. Acute renal failure in patients with drug-induced acute interstitial nephritis. Ren Fail. 1993;15:69–72 http://www.ncbi.nlm.nih.gov/pubmed/8441839. Accessed 1 Dec 2016.CrossRef

14.

Raza MN, Hadid M, Keen CE, Bingham C, Salmon AHJ. Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes. Nephrology (Carlton). 2012;17:748–53. https://doi.org/10.1111/j.1440-1797.2012.01648.x.CrossRefPubMed

15.

Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61. https://doi.org/10.1038/ki.2010.89.CrossRefPubMed

16.

Cameron JS. Allergic interstitial nephritis: clinical features and pathogenesis. Q J Med. 1988;66:97–115 http://www.ncbi.nlm.nih.gov/pubmed/3051085. Accessed 30 Nov 2016.PubMed

17.

Ulinski T, Sellier-Leclerc A-L, Tudorache E, Bensman A, Aoun B. Acute tubulointerstitial nephritis. Pediatr Nephrol. 2012;27:1051–7. https://doi.org/10.1007/s00467-011-1915-9.CrossRefPubMed

18.

Joyce E, Glasner P, Ranganathan S, Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr Nephrol. 2016. https://doi.org/10.1007/s00467-016-3394-5.

19.

González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73:940–6. https://doi.org/10.1038/sj.ki.5002776.CrossRefPubMed

20.

Meng X-M, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol. 2014;10:493–503. https://doi.org/10.1038/nrneph.2014.114.CrossRefPubMed

21.

Rossert JA, Garrett LA. Regulation of type I collagen synthesis. Kidney Int Suppl. 1995;49:S34–8 http://www.ncbi.nlm.nih.gov/pubmed/7674590. Accessed 9 Jan 2017.PubMed

22.

Zhu B, Jin Y, Han L, Chen H, Zhong F, Wang W, et al. Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts. Pharmacol Rep. 2013;65:1357–65 http://www.ncbi.nlm.nih.gov/pubmed/24399732. Accessed 7 Dec 2016.CrossRef

23.

Fu R-G, Wu J-J, Xue R-L, Zhang T, Wang L, Wu X-L, et al. Premature senescence and cellular phenotype transformation of mesangial cells induced by TGF-B ₁. Ren Fail. 2013;35:1142–5. https://doi.org/10.3109/0886022X.2013.817279.CrossRefPubMed

24.

Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92:2572–6 http://www.ncbi.nlm.nih.gov/pubmed/7708687. Accessed 9 Jan 2017.CrossRef

25.

Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest. 1996;74:991–1003 http://www.ncbi.nlm.nih.gov/pubmed/8667617. Accessed 9 Jan 2017.PubMed

26.

Wong MG, Pollock CA. Biomarkers in kidney fibrosis: are they useful? Kidney Int Suppl. 2014;4:79–83. https://doi.org/10.1038/kisup.2014.15.CrossRef

27.

Moledina DG, Perazella MA. Drug-Induced Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2017;12:2046–9. https://doi.org/10.2215/CJN.07630717.CrossRefPubMedPubMedCentral

28.

Galpin JE, Shinaberger JH, Stanley TM, Blumenkrantz MJ, Bayer AS, Friedman GS, et al. Acute interstitial nephritis due to methicillin. Am J Med. 1978;65:756–65 http://www.ncbi.nlm.nih.gov/pubmed/707534. Accessed 1 Dec 2016.CrossRef

29.

Prendecki M, Tanna A, Salama AD, Tam FWK, Cairns T, Taube D, et al. Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. Clin Kidney J. 2016;10:sfw116. https://doi.org/10.1093/ckj/sfw116.CrossRef

30.

Valluri A, Hetherington L, Mcquarrie E, Fleming S, Kipgen D, Geddes CC, et al. Acute tubulointerstitial nephritis in Scotland. QJM. 2015;108:527–32. https://doi.org/10.1093/qjmed/hcu236.CrossRefPubMed

31.

Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Biopsy-Proven Acute Interstitial Nephritis, 1993–2011: A Case Series. Am J Kidney Dis. 2014;64:558–66. https://doi.org/10.1053/j.ajkd.2014.04.027.CrossRefPubMed

32.

Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015;87:458–64. https://doi.org/10.1038/ki.2014.294.CrossRefPubMed

33.

Prednisolone product summary. http://produktresume.dk/AppBuilder/search?q=Prednison+DAK%2C+tabletter+5+mg+og+25+mg.doc. Accessed Sept 2020.

34.

Albert C, Haase M, Albert A, Zapf A, Braun-Dullaeus RC, Haase-Fielitz A. Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation? Ann Lab Med. 2021;41:1–15. https://doi.org/10.3343/alm.2021.41.1.1.CrossRefPubMedPubMedCentral

35.

Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin Chem Lab Med. 2017;55:1074–89. https://doi.org/10.1515/cclm-2016-0973.CrossRefPubMed

36.

Ho J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, et al. Urinary, Plasma, and Serum Biomarkers’ Utility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis. Am J Kidney Dis. 2015;66:993–1005. https://doi.org/10.1053/j.ajkd.2015.06.018.CrossRefPubMed

37.

Mishra OP, Rai AK, Srivastava P, Pandey K, Abhinay A, Prasad R, et al. Predictive ability of urinary biomarkers for outcome in children with acute kidney injury. Pediatr Nephrol. 2016. https://doi.org/10.1007/s00467-016-3445-y.

38.

Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, NGAL Meta-analysis Investigator Group. Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2009;54:1012–24. https://doi.org/10.1053/j.ajkd.2009.07.020.CrossRefPubMed

39.

Kimmel M, Shi J, Wasser C, Biegger D, Alscher MD, Schanz MB. Urinary [TIMP-2]·[IGFBP7] - Novel Biomarkers to Predict Acute Kidney Injury. Am J Nephrol. 2016;43:375–82. https://doi.org/10.1159/000446451.CrossRefPubMed

40.

Wu Y, Yang L, Su T, Wang C, Liu G, Li XM. Pathological Significance of a Panel of Urinary Biomarkers in Patients with Drug-Induced Tubulointerstitial Nephritis. Clin J Am Soc Nephrol. 2010;5:1954–9. https://doi.org/10.2215/CJN.02370310.CrossRefPubMedPubMedCentral

41.

Stefanović V, Djukanović L, Čukuranović R, Bukvić D, Ležaić V, Marić I, et al. Beta2-Microglobulin and Alpha1-Microglobulin as Markers of Balkan Endemic Nephropathy, a Worldwide Disease. Ren Fail. 2011;33:176–83. https://doi.org/10.3109/0886022X.2011.552152.CrossRefPubMed

42.

Robles NR, Lopez-Gomez J, Garcia-Pino G, Ferreira F, Alvarado R, Sanchez-Casado E, et al. Use of α1-microglobulin for diagnosing chronic interstitial nephropathy. Clin Exp Med. 2014;14:315–20. https://doi.org/10.1007/s10238-013-0242-9.CrossRefPubMed

43.

Pešić I, Stefanović V, Müller GA, Müller CA, Cukuranović R, Jahn O, et al. Identification and validation of six proteins as marker for endemic nephropathy. J Proteomics. 2011;74:1994–2007. https://doi.org/10.1016/j.jprot.2011.05.020.CrossRefPubMed

44.

Hettinga YM, Scheerlinck LME, Lilien MR, Rothova A, de Boer JH. The Value of Measuring Urinary β2-Microglobulin and Serum Creatinine for Detecting Tubulointerstitial Nephritis and Uveitis Syndrome in Young Patients With Uveitis. JAMA Ophthalmol. 2015;133:140. https://doi.org/10.1001/jamaophthalmol.2014.4301.CrossRefPubMed

45.

KDIGO Clinical Practice Guideline for Acute Kidney Injury. doi:https://doi.org/10.1038/kisup.2012.1.

46.

Disease K, Global Outcomes Diabetes Work Group I. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease; 2020. https://doi.org/10.1016/j.kint.2020.06.019.CrossRef

47.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12 http://www.ncbi.nlm.nih.gov/pubmed/19414839. Accessed 3 Apr 2017.CrossRef

48.

Terada I, Hyde C. The SF-36: An instrument for measuring quality of life in ESRD patients. EDTNA-ERCA J. 2002;28:73–83. https://doi.org/10.1111/j.1755-6686.2002.tb00206.x.CrossRefPubMed

49.

Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160–4. https://doi.org/10.1136/bmj.305.6846.160.CrossRefPubMedPubMedCentral

50.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, Mccann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017. https://doi.org/10.1016/j.kint.2017.04.006.

51.

Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622–31. https://doi.org/10.1056/NEJMoa1803537.CrossRefPubMedPubMedCentral

Title: Prednisolone treatment in acute interstitial nephritis (PRAISE) – protocol for the randomized controlled trial
Authors: Frank H. Mose
Henrik Birn
Nikolai Hoffmann-Petersen
Jesper N. Bech
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Interstitial Nephritis
Prednisolone
Published in: BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-021-02372-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Prevalence and correlates of malnutrition among hemodialysis patients at hebron governmental hospital, Palestine: cross-sectional study

Coding practice in national and regional kidney biopsy registries

Chronic kidney disease linked to SARS-CoV-2 infection: a case report

Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials

Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression

Regional citrate anticoagulation “non-shock” protocol with pre-calculated flow settings for patients with at least 6 L/hour liver citrate clearance

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage